Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 1, 2009, Pages 1-8

  Gabelt, B'Ann True ^a   Hennes, Elizabeth A ^a   Bendel, Mark A ^a   Constant, Chase E ^a   Okka, Mehmet ^a,b   Kaufman, Paul L ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b SELCUK UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

17 PHENYLTRINORPROSTAGLANDIN E2; BIMATOPROST; BUTAPROST; LATANOPROST; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; SULPROSTONE; TRAVOPROST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; INTRAOCULAR PRESSURE; MALE; MONKEY; NONHUMAN; SLIT LAMP;

ADMINISTRATION, TOPICAL; ALPROSTADIL; AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; DINOPROST; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HUMANS; INTRAOCULAR PRESSURE; MACACA FASCICULARIS; MALE; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; RECEPTORS, PROSTAGLANDIN; RECEPTORS, PROSTAGLANDIN E; TONOMETRY, OCULAR;

EID: 61749098216     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2008.0089     Document Type: Article

References (34)

1. Stjernschantz, J., Selén, G., Ocklind, A., et al. Effects of latanoprost and related prostaglandin analogues. In: A. Alm, and Weinreb, R.N., eds., Uveoscleral Outflow. Biology and Clinical Aspects. London: Mosby-Wolfe Medical Communications, 1998:57-72.
2. Sharif, N.A., Kelly, C.R., Crider, J.Y., et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J. Ocul. Pharmacol. Ther. 19:501-515, 2003.
3. Stjernschantz, J.W. From PGF2a-isopropyl ester to latanoprost: A review of the development of Xalatan. The Proctor Lecture. Invest. Ophthalmol. Vis. Sci. 42:1134-1145, 2001.
4. Bito, L.Z. A new approach to the medical management of glaucoma, from the bench to the clinic, and beyond [Proctor lecture]. Invest. Ophthalmol. Vis. Sci. 42:1126-1133, 2001.
5. 2a on aqueous humor dynamics in cynomolgus monkeys. Curr. Eye Res. 6:1035-1044, 1987.
6. Alexander, C.L., Miller, S.J., and Abel, S.R. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann. Pharmacother. 36:504-511, 2002.
7. Eisenberg, D.L., Toris, C.B., and Camras, C.B. Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs. Surv. Ophthalmol. 47:S105-S115, 2002.
8. Coleman, R.A., Kennedy, I., Humphrey, P.P.A., et al. Prostanoids and their Receptors. In: Sammes, P.G., and Taylor, J.B., eds., "Comprehensive Medicinal Chemistry: The Rational Design, Mechanistic Study, & Therapeutic Application of Chemical Compounds," 1st ed. New York: Pergamon Press, 1990:643-714.
9. 2+ mobilization, and MAP kinase activation. J. Ocul. Pharmacol. Ther. 19:437-455, 2003.
10. Bhattacherjee, P., Shawn Williams, B., and Paterson, C.A., Responses of intraocular pressure and the pupil of feline eyes to prostaglandin EP1 and FP receptor agonists. Invest. Ophthalmol. Vis. Sci. 40:3047-3053, 1999.
11. Lawrence, R.A., Jones, R.L., and Wilson, N.H. Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum. Br. J. Pharmacol. 105:271-278, 1992.
12. Bhattacherjee, P., Mukhopadhyay, P., Tilley, S.L., et al. Blood-aqueous barrier in prostaglandin EP2 receptor knockout mice. Ocul. Immunol. Inflamm. 10:87-196, 2002.
13. Coleman, R.A., Kennedy, I., and Sheldrick, R.L. New evidence with selective agonists and antagonists for the subclassification of PGE2-sensitive (EP) receptors. Adv. PG. Tx. Lt. Res. 17A:467-470, 1987.
14. Abramovitz, M., Adam, M., Boie, Y., et al. The utilization of recombinant prostanoid receptors to determine the affinities annd selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta. 1483:285-293, 2000.
15. Croft, M.A., Kiland, J., Gange, S.J., et al. Comparison of Goldmann tonometry measurements using creamer vs fluorescein in cynomolgus monkeys. In: Lakshminarayanan, V., ed., "Basic and Clinical Applications of Vision Science. The Professore Jay M. Enoch Festschrift Volume, Documenta Ophthalmologica Proceedings Series, Vol 60." Dorderecht: Kluwer, 213-216, 1997.
16. Kaufman, P.L., and Davis, G.E. "Minified" Goldmann applanating prism for tonometry in monkeys and humans. Arch. Ophthalmol. 98:542-546, 1980.
17. Gabelt, B.T., and Kaufman, P.L. Bimatoprost for glaucoma therapy: Pharmacology, clinical efficacy, and controversy. Exp. Rev. Ophthalmol. 1:141-158, 2006.
18. Gandolfi, S.A., and Cimino, L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 110:609-614, 2003.
19. Sonty, S., Donthamsetti, V., Vangipuram, G., et al. Long-term IOP lowering with bimatoprost in open-angle glaucoma patients poorly responsive to latanoprost. J. Ocul. Pharmacol. Ther. 24:517-520, 2008.
20. Biswas, S., Bhattacherjee, P., and Paterson, C.A. Prostaglandin E2 receptor subtypes, EP1, EP2, EP3 and EP4, in human and mouse ocular tissues - a comparative immunohistochemical study. Prostagl. Leukot. Essent. Fatty. Acids 71:277-288, 2004.
21. Schlotzer-Schrebardt, U., Zenkel, M., and Nusing, R.M. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest. Ophthalmol. Vis. Sci. 43:1475-1487, 2002.
22. Mukhopadhyay, P., Bian, L., Yin, H., et al. Localization of EP(1) and FP receptors in human ocular tissues by in situ hybridization. Invest. Ophthalmol. Vis. Sci. 42:424-428, 2001.
23. Nilsson, S.F., Drecoll, E., Lutjen-Drecoll, E., et al. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest. Ophthalmol. Vis. Sci. 47:4042-4049, 2006.
24. Woodward, D.F., Lawrence, R.A., Fairbairn, C.E., et al. Intraocular pressure effects of selective prostanoid receptor agonists involve different receptor subtypes according to radioligand-binding studies. J. Lipid. Metab. 6:545-553, 1993.
25. Ota, T., Aihara, M., Saeki, T., et al. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice. Br. J. Ophthalmol. 91:673-676, 2007.
26. Ota, T., Aihara, M., Saeki, T., et al. The effects of prostaglandin analoques on prostaoid EP1, EP2, and EP3 receptor-deficient mice. Invest. Ophthalmol. Vis. Sci. 47:3395-3399, 2006.
27. Kharlamb, A.B., Krauss, A.H., Chen, J., et al. Prostanoid EP4 receptor stimulation produces profound ocular hypotension that involves pressure dependent outflow. Invest. Ophthalmol. Vis. Sci. 45(Suppl):Abs nr 1035, 2004.
28. Kharlamb, A.B., Woodward, D.F., Burk, R.M., et al. Ciliary muscle relaxation does not explain the profound ocular hypotension produced by a selective prostanoid EP4 receptor agonist 3,7-dithia PGE1 in monkeys. Invest. Ophthalmol. Vis. Sci. ARVO supplement:Abs nr 413, 2006.
29. 2a increases uveoscleral outflow in the cynomolgus monkey. Exp. Eye Res. 49:389-402, 1989.
30. 2a-1-isopropylester in the cynomolgus monkey. Exp. Eye. Res. 48:707-716, 1989.
31. 2a on trabecular outflow facility in cynomolgus monkeys. Exp. Eye. Res. 51:87-91, 1990.
32. Richter, M., Krauss, A.H-P., Woodward, D.F., et al. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest. Ophthalmol. Vis. Sci. 44:4419-4426, 2003.
33. Weinreb, R.N., Lindsey, J.D., Marchenko, G., et al. Prostaglandin FP agonists alter metalloproteinase gene expression in sclera. Invest. Ophthalmol. Vis. Sci. 45:4368-4377, 2004.
34. Kim, J-W., Lindsey, J.D., Wang, N., et al. Increased human scleral permeability with prostaglandin exposure. Invest. Ophthalmol. Vis. Sci. 42:1514-1521, 2001.